Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Monoclonal Antibody for Patients with Covid-19. Reply

    Publikation: Bidrag til tidsskriftLetterpeer review

  5. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

    Publikation: Bidrag til tidsskriftLetterpeer review

  3. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kirsten Fischer
  • Othman Al-Sawaf
  • Jasmin Bahlo
  • Anna-Maria Fink
  • Maneesh Tandon
  • Mark Dixon
  • Sandra Robrecht
  • Simon Warburton
  • Kathryn Humphrey
  • Olga Samoylova
  • Anna M Liberati
  • Javier Pinilla-Ibarz
  • Stephen Opat
  • Liliya Sivcheva
  • Katell Le Dû
  • Laura M Fogliatto
  • Carsten U Niemann
  • Robert Weinkove
  • Sue Robinson
  • Thomas J Kipps
  • Sebastian Boettcher
  • Eugen Tausch
  • Rod Humerickhouse
  • Barbara Eichhorst
  • Clemens-Martin Wendtner
  • Anton W Langerak
  • Karl-Anton Kreuzer
  • Matthias Ritgen
  • Valentin Goede
  • Stephan Stilgenbauer
  • Mehrdad Mobasher
  • Michael Hallek
Vis graf over relationer

BACKGROUND: The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.

METHODS: In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions. Patients with a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, with higher scores indicating more impaired function of organ systems) or a calculated creatinine clearance of less than 70 ml per minute were randomly assigned to receive venetoclax-obinutuzumab or chlorambucil-obinutuzumab. The primary end point was investigator-assessed progression-free survival. The safety of each regimen was also evaluated.

RESULTS: In total, 432 patients (median age, 72 years; median Cumulative Illness Rating Scale score, 8; median creatinine clearance, 66.4 ml per minute) underwent randomization, with 216 assigned to each group. After a median follow-up of 28.1 months, 30 primary end-point events (disease progression or death) had occurred in the venetoclax-obinutuzumab group and 77 had occurred in the chlorambucil-obinutuzumab group (hazard ratio, 0.35; 95% confidence interval [CI], 0.23 to 0.53; P<0.001). The Kaplan-Meier estimate of the percentage of patients with progression-free survival at 24 months was significantly higher in the venetoclax-obinutuzumab group than in the chlorambucil-obinutuzumab group: 88.2% (95% CI, 83.7 to 92.6) as compared with 64.1% (95% CI, 57.4 to 70.8). This benefit was also observed in patients with TP53 deletion, mutation, or both and in patients with unmutated immunoglobulin heavy-chain genes. Grade 3 or 4 neutropenia occurred in 52.8% of patients in the venetoclax-obinutuzumab group and in 48.1% of patients in the chlorambucil-obinutuzumab group, and grade 3 or 4 infections occurred in 17.5% and 15.0%, respectively. All-cause mortality was 9.3% in the venetoclax-obinutuzumab group and 7.9% in the chlorambucil-obinutuzumab group. These differences were not significant.

CONCLUSIONS: Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind380
Udgave nummer23
Sider (fra-til)2225-2236
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 6 jun. 2019

Bibliografisk note

Copyright © 2019 Massachusetts Medical Society.

ID: 57444084